Apr 16, 09:08
82% of moneycontrol users recommend buying Cipla. What's your call on Cipla today? Read 20 investor views
|Company Name||Last Price||%
|Dr Reddys Labs||2542.05||-1.37||2939.80||1901.00||43,242.52|
|Dec' 13||Sep' 13||Jun' 13||Mar' 13|
|Scheme||No. of Shares|
|HDFC Tax Saver (G)||2,320,083|
|HDFC Top 200 Fund (G)||2,275,985|
|HDFC Equity Fund (G)||1,950,614|
|DSP BlackRock Top 100 Equity Fund - Regular Plan (G)||1,710,353|
Cipla is in the Pharmaceuticals sector. The current market capitalisation stands at Rs 31,659.19 crore.The company has reported a consolidated sales of Rs 2,552.63 crore and a Net Profit of Rs 296.53 crore for the quarter ended Dec 2013.
The company management includes Y K Hamied - Executive Vice Chairman, Subhanu Saxena - Managing Director & Global CEO, M K Hamied - Managing Director, S Radhakrishnan - Whole Time Director, H R Manchanda - Non Executive Director, V C Kotwal - Non Executive Director, M R Raghavan - Non Executive Director, Pankaj Patel - Non Executive Director, Ramesh Shroff - Non Executive Director, Ashok Sinha - Additional Director, Peter Mugyenyi - Independent Director.
It is listed on the BSE with a BSE Code of 500087 and the NSE with an NSE Code of CIPLA.
Its Registered office is at Mumbai Central , Mumbai,Maharashtra - 400008.
Their Registrars are Karvy Computershare Private Ltd.